Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:
“HB0025 phase 2, JAMA Oncology:
PD-L1×VEGF BsAb+chemo, 1L driver-neg NSCLC (n=169)
- ORR 20 mg/kg: nsq 57.1%, sq 74.2%
- mPFS nsq 12.52, sq 14.78 mo
- G≥3 TRAEs nsq 65.9%, sq 60.7%.
Room for another PD-(L)1×VEGF BsAb?”
Title: HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer – A Phase 2 Nonrandomized Clinical Trial
Authors: Fei Zhou, Lei Wang, Jinghui Bai, Fang Yang, Meili Sun, Qiming Wang, Shegan Gao, Guohua Yu, Yu Yao, Jianhua Shi, Aimin Zang, Xiaodong Jiang, Jianya Zhou, Xia Song, Xiangyang Zhu, Bo Xu, Yifan Zhan, Xiaopei Cui, Xiuqiang Ma, Benke Li, Jinhua Wang, Ye Cai, Caicun Zhou
You can also explore:
LungÕ 2026: Integrating Care and Advancing Treatment for Locally Advanced Lung Cancer
